Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19x22 CAR T in R/R B-NHL
NCT05098613Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19x22 CAR T cells in B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) and central nervous system lymphoma (3 cohorts), sponsored by University of Colorado Denver. Primary endpoints: Overall safety and tolerability of CD19x22 CAR T Therapy at 12 months and Recommended Phase II Dose at 30 days. Started Dec 2021; status: recruiting.
02
Drugs
CD19x22 CAR T cells
03
Conditions
B-cell non-Hodgkin lymphomamantle cell lymphoma (MCL)central nervous system lymphoma
Beyond the preview
Go deeper on NCT05098613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098613.